BELGRADE, Serbia—Dapagliflozin (Farxiga; AstraZeneca) does not further improve quality of life in older patients with aortic stenosis and a history of heart failure (HF) undergoing TAVI despite ...

Treatment with dapagliflozin reduced the risk of death or worsening heart failure by 28% compared with standard of care. Dapagliflozin reduced the risk of death or worsening heart failure (HF) in ...

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

The DapaTAVI trial previously showed reduced rates of death or worsening heart failure with dapagliflozin in older adults with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as ...